A review on the role of gamma-butyrobetaine hydroxylase 1 antisense RNA 1 in the carcinogenesis and tumor progression.
BBOX1-AS1
CeRNA network
Predictive biomarker
Signaling pathway
Tumors
Journal
Cancer cell international
ISSN: 1475-2867
Titre abrégé: Cancer Cell Int
Pays: England
ID NLM: 101139795
Informations de publication
Date de publication:
05 Nov 2023
05 Nov 2023
Historique:
received:
02
08
2023
accepted:
27
10
2023
medline:
5
11
2023
pubmed:
5
11
2023
entrez:
5
11
2023
Statut:
epublish
Résumé
Gamma-butyrobetaine hydroxylase 1 antisense RNA 1 (BBOX1-AS1), located on human chromosome 11 p14, emerges as a critical player in tumorigenesis with diverse oncogenic effects. Aberrant expression of BBOX1-AS1 intricately regulates various cellular processes, including cell growth, epithelial-mesenchymal transition, migration, invasion, metastasis, cell death, and stemness. Notably, the expression of BBOX1-AS1 was significantly correlated with clinical-pathological characteristics and tumor prognoses, and it could also be used for the diagnosis of lung and esophageal cancers. Through its involvement in the ceRNA network, BBOX1-AS1 competitively binds to eight miRNAs in ten different cancer types. Additionally, BBOX1-AS1 can directly modulate downstream protein-coding genes or act as an mRNA stabilizer. The implications of BBOX1-AS1 extend to critical signaling pathways, including Hedgehog, Wnt/β-catenin, and MELK/FAK pathways. Moreover, it influences drug resistance in hepatocellular carcinoma. The present study provides a systematic review of the clinical significance of BBOX1-AS1's aberrant expression in diverse tumor types. It sheds light on the intricate molecular mechanisms through which BBOX1-AS1 influences cancer initiation and progression and outlines potential avenues for future research in this field.
Identifiants
pubmed: 37925403
doi: 10.1186/s12935-023-03113-3
pii: 10.1186/s12935-023-03113-3
pmc: PMC10625699
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
263Subventions
Organisme : Natural Science Foundation of Jiangxi Province
ID : S2020ZRMSB0672
Informations de copyright
© 2023. The Author(s).
Références
Signal Transduct Target Ther. 2020 Dec 2;5(1):279
pubmed: 33262323
Bioengineered. 2022 Apr;13(4):11138-11153
pubmed: 35506252
Biol Reprod. 2023 Mar 13;108(3):408-422
pubmed: 36617174
Int J Oncol. 2021 Nov;59(5):
pubmed: 34698360
Mol Ther Oncolytics. 2022 Dec 23;28:88-103
pubmed: 36699616
Int J Mol Sci. 2023 Mar 27;24(7):
pubmed: 37047267
Biomed Pharmacother. 2022 Feb;146:112251
pubmed: 34916087
Bioengineered. 2022 May;13(5):13407-13421
pubmed: 36700475
Cell Death Dis. 2021 Dec 21;13(1):25
pubmed: 34934045
Nat Rev Mol Cell Biol. 2021 Feb;22(2):96-118
pubmed: 33353982
Nat Rev Mol Cell Biol. 2023 Jun;24(6):430-447
pubmed: 36596869
Pathol Res Pract. 2023 Jul;247:154545
pubmed: 37244053
Mol Cancer. 2019 Oct 25;18(1):147
pubmed: 31651347
Cell Oncol (Dordr). 2023 Oct;46(5):1381-1398
pubmed: 37138146
Pharmacol Ther. 2015 Feb;146:132-49
pubmed: 25316657
Development. 2014 Sep;141(18):3445-57
pubmed: 25183867
J Clin Invest. 2009 Jun;119(6):1420-8
pubmed: 19487818
J Exp Clin Cancer Res. 2021 Apr 30;40(1):148
pubmed: 33931086
FEBS Open Bio. 2022 May;12(5):983-992
pubmed: 31984680
Ann Clin Lab Sci. 2023 May;53(3):366-379
pubmed: 37437933
Curr Mol Pharmacol. 2023;16(8):894-904
pubmed: 36717994
Mol Med Rep. 2023 Aug;28(2):
pubmed: 37350380
Cancer Lett. 2023 Feb 1;554:216007
pubmed: 36396102
Front Oncol. 2020 Dec 18;10:598817
pubmed: 33392092
Nat Rev Genet. 2009 Mar;10(3):155-9
pubmed: 19188922
Int J Mol Sci. 2013 Sep 12;14(9):18790-808
pubmed: 24036441
Noncoding RNA Res. 2022 Dec 14;8(2):135-145
pubmed: 36605618
Cancer Cell Int. 2022 Jul 5;22(1):225
pubmed: 35790972
Cell Prolif. 2022 Jan;55(1):e13162
pubmed: 34918401
Genome Res. 2012 Sep;22(9):1646-57
pubmed: 22955977
Biomed Pharmacother. 2023 Jul;163:114756
pubmed: 37105079
Med Res Rev. 2023 Sep;43(5):1263-1321
pubmed: 36951271
Pflugers Arch. 2022 Feb;474(2):191-204
pubmed: 34791525
Front Cell Dev Biol. 2023 May 11;11:1149499
pubmed: 37250901
Reprod Sci. 2021 Mar;28(3):736-744
pubmed: 33159291
J Biol Regul Homeost Agents. 2021 Jul 19;35(4):
pubmed: 34278772
Exp Cell Res. 2022 Jun 1;415(1):113117
pubmed: 35351402
J Hematol Oncol. 2013 May 31;6:37
pubmed: 23725405
Taiwan J Obstet Gynecol. 2021 Mar;60(2):253-261
pubmed: 33678324
Heliyon. 2023 Mar 01;9(3):e14143
pubmed: 36950593
Biotechniques. 2013 Jun;54(6):301, 303-4
pubmed: 23750541
Organogenesis. 2008 Apr;4(2):68-75
pubmed: 19279717
Front Oncol. 2021 Jul 22;11:696705
pubmed: 34367979
Proc Natl Acad Sci U S A. 2013 Apr 30;110(18):7112-3
pubmed: 23620514
Cancer Metastasis Rev. 2023 Mar;42(1):197-215
pubmed: 36757577
Aging (Albany NY). 2022 Jan 6;14(1):368-388
pubmed: 34990401
Mol Cancer. 2023 Mar 1;22(1):41
pubmed: 36859185
Cancer Cell Int. 2023 Jul 4;23(1):130
pubmed: 37403096
Ther Adv Med Oncol. 2010 Jul;2(4):237-50
pubmed: 21789137
Cell Prolif. 2020 Jul;53(7):e12823
pubmed: 32515533
RNA Biol. 2010 Sep-Oct;7(5):582-5
pubmed: 20930520
Genes Dis. 2022 Jun 29;10(3):901-914
pubmed: 37396533
Biol Direct. 2023 Jul 4;18(1):36
pubmed: 37403106
Eur J Pharmacol. 2022 Nov 5;934:175317
pubmed: 36216119
Biochem Genet. 2023 Aug;61(4):1351-1368
pubmed: 36586008
Clin Transl Med. 2015 Mar 07;4:11
pubmed: 25852826
Cancer Manag Res. 2021 Dec 08;13:9049-9062
pubmed: 34938119
Cells. 2018 Nov 10;7(11):
pubmed: 30423843
Bioengineered. 2022 Mar;13(3):6092-6099
pubmed: 35188872
Pathol Res Pract. 2023 Aug;248:154657
pubmed: 37451194
Oncol Lett. 2022 Jan;23(1):17
pubmed: 34820016
Eur J Clin Invest. 2023 Apr;53(4):e13929
pubmed: 36453878
Nat Rev Cancer. 2014 Sep;14(9):598-610
pubmed: 25098269
Oncogene. 2017 Mar;36(11):1461-1473
pubmed: 27617575
Cancer Lett. 2013 Oct 10;339(2):159-66
pubmed: 23791884
Semin Cancer Biol. 2023 Oct;95:1-12
pubmed: 37364663
Proc Natl Acad Sci U S A. 2023 Jun 6;120(23):e2220037120
pubmed: 37252980
Int J Mol Sci. 2023 Apr 30;24(9):
pubmed: 37175800
Stem Cell Rev Rep. 2023 Aug;19(6):1577-1595
pubmed: 37129728
J Cell Mol Med. 2023 Jul;27(14):1928-1946
pubmed: 37246627
Anticancer Drugs. 2022 Aug 1;33(7):652-662
pubmed: 35324526
Int J Mol Sci. 2022 Feb 02;23(3):
pubmed: 35163650
Chem Biol Drug Des. 2023 May;101(5):1151-1161
pubmed: 35993390
Cancer Biother Radiopharm. 2022 Dec;37(10):893-906
pubmed: 33481661
J Transl Med. 2023 Jun 12;21(1):382
pubmed: 37308993
J Hematol Oncol. 2015 Mar 28;8:30
pubmed: 25888444
Biomed Pharmacother. 2023 Jun;162:114692
pubmed: 37058817
Development. 2018 Jun 8;145(11):
pubmed: 29884654
Biomed Pharmacother. 2021 Jan;133:110946
pubmed: 33212376
J Cancer. 2021 May 5;12(13):3754-3768
pubmed: 34093785
Cell Death Discov. 2022 Jun 14;8(1):287
pubmed: 35697671
Nat Rev Mol Cell Biol. 2023 Sep;24(9):668-687
pubmed: 36932157
J Hematol Oncol. 2022 Sep 8;15(1):129
pubmed: 36076302